AI assistant
Dermata Therapeutics, Inc. — Director's Dealing 2021
Aug 13, 2021
35467_dirs_2021-08-12_c57ff5d1-1cd6-4093-819f-a5fd91260088.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Dermata Therapeutics, Inc. (DRMA)
CIK: 0001853816
Period of Report: 2021-08-12
Reporting Person: WIERENGA WENDELL (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4878 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.74 | 2031-03-31 | Common Stock (12194) | Direct | |
| Stock Option (Right to Buy) | $5.74 | 2031-03-31 | Common Stock (4878) | Direct | |
| Series 1d Preferred Stock | $ | Common Stock (55078) | Direct |
Footnotes
F1: Shares reported reflect the 1 for 20.5 stock split effected July 1, 2021 (the "Stock Split").
F2: Options vest in 12 equal monthly installments commencing January 1, 2021.
F3: The Series 1d Preferred Stock is convertible into shares of Common Stock at a conversion ratio equal to 80% of the offering price in connection with the Issuer's initial public offering ("IPO"). Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the IPO, all shares of Series 1d Preferred Stock will be converted into 8,163 shares of Common Stock of the Issuer. The conversion ratio reflects the Stock Split.